Valence8 US’s Blueprint Medicines BPMC Stock Holding History

Valence8 US’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,618	Closed	-$242K	–	25
2024 Q3	$242K	Buy	+2,618	New	+$260K	0.1%	40

Other funds holding BPMC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Valence8 US's BPMC Position: Q4 2024 in Review

Valence8 US sold out of Blueprint Medicines (BPMC) in Q4 2024, closing a stake of 2,618 shares — an estimated $242K sold.

Valence8 US first reported a position in BPMC in Q3 2024 and held it in 1 quarter. The position peaked at $242K in Q3 2024. 345 funds tracked by Wall St. Rank hold BPMC as of Q4 2024.

Valence8 US reported no remaining Blueprint Medicines position as of Q4 2024 after selling out during the quarter.
Valence8 US sold 2,618 Blueprint Medicines shares in Q4 2024, an estimated $242K.
Valence8 US first reported a position in Blueprint Medicines in Q3 2024 and held it in 1 quarter.
Valence8 US's Blueprint Medicines position peaked at $242K in Q3 2024.
345 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2024.

Based on Valence8 US's 13F filing for Q4 2024, filed 12 Feb 2025.